InvestorsHub Logo
Followers 840
Posts 120470
Boards Moderated 18
Alias Born 09/05/2002

Re: None

Friday, 02/25/2022 11:31:20 AM

Friday, February 25, 2022 11:31:20 AM

Post# of 1168
BHVN licenses SMA drug candidate—taldefgrobep alfa (a/k/a BMS-986089) from BMY for undisclosed milestone payments and royalties:

https://finance.yahoo.com/news/biohaven-licenses-taldefgrobep-alfa-phase-115000615.html

Under the terms of the agreement, Biohaven will receive worldwide rights to taldefgrobep and Bristol Myers Squibb will be eligible for regulatory approval milestone payments, as well as tiered, sales-based royalties beginning in the high teens.

This drug previously failed in clincial trials run by BMY/Roche, so BHVN must have a new angle.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News